

# Richter's Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033

<https://marketpublishers.com/r/RF33B0307620EN.html>

Date: March 2023

Pages: 315

Price: US\$ 5,499.00 (Single User License)

ID: RF33B0307620EN

## Abstracts

The Richter's syndrome market size in top seven countries reached US\$ 430.5 Million in 2022. Looking forward, IMARC Group expects the market in top seven countries to reach US\$ 685.7 Million by 2032, exhibiting a growth rate (CAGR) of 4.3% during 2023-2033.

Richter's syndrome, also known as Richter's transformation, is a rare and aggressive form of cancer that develops in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Some of the symptoms indicative of the disease are rapidly enlarging lymph nodes, fever, weight loss, night sweats, fatigue, decreased appetite, abdominal pain or swelling, shortness of breath, headaches, etc. The diagnosis of Richter's syndrome involves a combination of physical exams, blood tests, imaging studies, and tissue biopsies. The diagnostic tests include a complete blood count (CBC) to measure the number of different types of blood cells, flow cytometry to identify the type of cancer cells present in the blood or bone marrow, and imaging studies such as CT, PET, or MRI scans to detect the extent and location of the cancer cells. The most definitive diagnostic test is a tissue biopsy, in which a sample of the affected tissue is removed and examined under a microscope. Once the diagnosis of Richter's syndrome has been made, further investigations may be conducted to determine the extent of the disease and guide treatment decisions.

The rising prevalence of aggressive lymphoma in individuals with chronic lymphocytic leukemia and small lymphocytic lymphoma is primarily driving the Richter's syndrome market. In addition to this, the widespread adoption of targeted therapy, which involves the use of drugs that target the B-cell receptor pathway to treat the ailment, particularly in patients who are not candidates for chemotherapy, is creating a positive outlook for

the market. Moreover, the ongoing development of several diagnostic tools, such as flow cytometry, molecular testing, imaging studies like PET-CT, etc., which assist in distinguishing Richter's syndrome from other types of lymphoma and improving the accuracy of diagnosis, is also bolstering the market growth. Apart from this, the emerging popularity of stem cell transplantation, a high-dose therapy that uses chemotherapy or radiation to destroy the patient's bone marrow and replace it with healthy stem cells, especially among younger patients who are not responding to other therapies, is further propelling the market growth. Moreover, several key players are making extensive investments in clinical trials to evaluate the safety and efficacy of novel therapies for Richter's syndrome, such as CAR T-cell therapy, which involves engineering patient's own T-cells to target and kill cancer cells. This, in turn, is also acting as another significant growth-inducing factor. Additionally, the increasing utilization of immune checkpoint inhibitors, which block proteins from binding together and increase the response strength of T-cells against cancer cells, for treating the ailment is expected to drive the Richter's syndrome market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Richter's syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Richter's syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Richter's syndrome market in any manner.

#### Time Period of the Study

Base Year: 2022

Historical Period: 2017-2022

Market Forecast: 2023-2033

#### Countries Covered

United States

Germany  
France  
United Kingdom  
Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the Richter's syndrome market  
Historical, current, and future performance of various therapeutic categories in the market  
Sales of various drugs across the Richter's syndrome market  
Reimbursement scenario in the market  
In-market and pipeline drugs

This report also provides a detailed analysis of the current Richter's syndrome marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Regulatory Status  
Key Questions Answered in this Report  
Market Insights

How has the Richter's syndrome market performed so far and how will it perform in the

coming years?

What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?

What was the country-wise size of the Richter's syndrome market across the seven major markets in 2022 and what will it look like in 2033?

What is the growth rate of the Richter's syndrome market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2017-2033) of Richter's syndrome across the seven major markets?

What is the number of prevalent cases (2017-2033) of Richter's syndrome by age across the seven major markets?

What is the number of prevalent cases (2017-2033) of Richter's syndrome by gender across the seven major markets?

How many patients are diagnosed (2017-2033) with Richter's syndrome across the seven major markets?

What is the size of the Richter's syndrome patient pool (2017-2022) across the seven major markets?

What would be the forecasted patient pool (2023-2033) across the seven major markets?

What are the key factors driving the epidemiological trend of Richter's syndrome?

What will be the growth rate of patients across the seven major markets?

### Richter's Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for Richter's syndrome drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Richter's syndrome market?

What are the key regulatory events related to the Richter's syndrome market?

What is the structure of clinical trial landscape by status related to the Richter's syndrome market?

What is the structure of clinical trial landscape by phase related to the Richter's syndrome market?

What is the structure of clinical trial landscape by route of administration related to the Richter's syndrome market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 RICHTER'S SYNDROME - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2017-2022) and Forecast (2023-2033)
- 4.4 Market Overview (2017-2022) and Forecast (2023-2033)
- 4.5 Competitive Intelligence

### **5 RICHTER'S SYNDROME - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 RICHTER'S SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2017-2022)
  - 7.2.2 Epidemiology Forecast (2023-2033)
  - 7.2.3 Epidemiology by Age (2017-2033)
  - 7.2.4 Epidemiology by Gender (2017-2033)
  - 7.2.5 Diagnosed Cases (2017-2033)
  - 7.2.6 Patient Pool/Treated Cases (2017-2033)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2017-2022)
  - 7.3.2 Epidemiology Forecast (2023-2033)
  - 7.3.3 Epidemiology by Age (2017-2033)
  - 7.3.4 Epidemiology by Gender (2017-2033)
  - 7.3.5 Diagnosed Cases (2017-2033)
  - 7.3.6 Patient Pool/Treated Cases (2017-2033)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2017-2022)
  - 7.4.2 Epidemiology Forecast (2023-2033)
  - 7.4.3 Epidemiology by Age (2017-2033)
  - 7.4.4 Epidemiology by Gender (2017-2033)
  - 7.4.5 Diagnosed Cases (2017-2033)
  - 7.4.6 Patient Pool/Treated Cases (2017-2033)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2017-2022)
  - 7.5.2 Epidemiology Forecast (2023-2033)
  - 7.5.3 Epidemiology by Age (2017-2033)
  - 7.5.4 Epidemiology by Gender (2017-2033)
  - 7.5.5 Diagnosed Cases (2017-2033)
  - 7.5.6 Patient Pool/Treated Cases (2017-2033)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2017-2022)
  - 7.6.2 Epidemiology Forecast (2023-2033)
  - 7.6.3 Epidemiology by Age (2017-2033)
  - 7.6.4 Epidemiology by Gender (2017-2033)
  - 7.6.5 Diagnosed Cases (2017-2033)
  - 7.6.6 Patient Pool/Treated Cases (2017-2033)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2017-2022)
  - 7.7.2 Epidemiology Forecast (2023-2033)
  - 7.7.3 Epidemiology by Age (2017-2033)

- 7.7.4 Epidemiology by Gender (2017-2033)
- 7.7.5 Diagnosed Cases (2017-2033)
- 7.7.6 Patient Pool/Treated Cases (2017-2033)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2017-2022)
  - 7.8.2 Epidemiology Forecast (2023-2033)
  - 7.8.3 Epidemiology by Age (2017-2033)
  - 7.8.4 Epidemiology by Gender (2017-2033)
  - 7.8.5 Diagnosed Cases (2017-2033)
  - 7.8.6 Patient Pool/Treated Cases (2017-2033)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2017-2022)
  - 7.9.2 Epidemiology Forecast (2023-2033)
  - 7.9.3 Epidemiology by Age (2017-2033)
  - 7.9.4 Epidemiology by Gender (2017-2033)
  - 7.9.5 Diagnosed Cases (2017-2033)
  - 7.9.6 Patient Pool/Treated Cases (2017-2033)

## **8 RICHTER'S SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 RICHTER'S SYNDROME - UNMET NEEDS**

## **10 RICHTER'S SYNDROME - KEY ENDPOINTS OF TREATMENT**

## **11 RICHTER'S SYNDROME - MARKETED PRODUCTS**

- 11.1 List of Richter's Syndrome Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Drug Name – Company Name
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report



## **12 RICHTER'S SYNDROME - PIPELINE DRUGS**

### 12.1 List of Richter's Syndrome Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 Pembrolizumab - Merck & Co

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

#### 12.1.2 Blinatumomab - Amgen

##### 12.1.2.1 Drug Overview

##### 12.1.2.2 Mechanism of Action

##### 12.1.2.3 Clinical Trial Results

##### 12.1.2.4 Safety and Efficacy

##### 12.1.2.5 Regulatory Status

#### 12.1.3 Acalabrutinib - Acerta Pharma/AstraZeneca

##### 12.1.3.1 Drug Overview

##### 12.1.3.2 Mechanism of Action

##### 12.1.3.3 Clinical Trial Results

##### 12.1.3.4 Safety and Efficacy

##### 12.1.3.5 Regulatory Status

#### 12.1.4 Cosibelimab - Checkpoint Therapeutics/TG Therapeutics

##### 12.1.4.1 Drug Overview

##### 12.1.4.2 Mechanism of Action

##### 12.1.4.3 Clinical Trial Results

##### 12.1.4.4 Safety and Efficacy

##### 12.1.4.5 Regulatory Status

#### 12.1.5 Duvelisib - Secura Bio

##### 12.1.5.1 Drug Overview

##### 12.1.5.2 Mechanism of Action

##### 12.1.5.3 Clinical Trial Results

##### 12.1.5.4 Safety and Efficacy

##### 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report

## **13. RICHTER'S SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. RICHTER'S SYNDROME – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

## **15 RICHTER'S SYNDROME - MARKET SCENARIO**

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
  - 15.2.1 Richter's Syndrome - Market Size
    - 15.2.1.1 Market Size (2017-2022)
    - 15.2.1.2 Market Forecast (2023-2033)
  - 15.2.2 Richter's Syndrome - Market Size by Therapies
    - 15.2.2.1 Market Size by Therapies (2017-2022)
    - 15.2.2.2 Market Forecast by Therapies (2023-2033)
- 15.3 Market Scenario - United States
  - 15.3.1 Richter's Syndrome - Market Size
    - 15.3.1.1 Market Size (2017-2022)
    - 15.3.1.2 Market Forecast (2023-2033)
  - 15.3.2 Richter's Syndrome - Market Size by Therapies
    - 15.3.2.1 Market Size by Therapies (2017-2022)
    - 15.3.2.2 Market Forecast by Therapies (2023-2033)
  - 15.3.3 Richter's Syndrome - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Richter's Syndrome - Market Size
    - 15.4.1.1 Market Size (2017-2022)
    - 15.4.1.2 Market Forecast (2023-2033)
  - 15.4.2 Richter's Syndrome - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2017-2022)
    - 15.4.2.2 Market Forecast by Therapies (2023-2033)
  - 15.4.3 Richter's Syndrome - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Richter's Syndrome - Market Size
    - 15.5.1.1 Market Size (2017-2022)
    - 15.5.1.2 Market Forecast (2023-2033)
  - 15.5.2 Richter's Syndrome - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2017-2022)

- 15.5.2.2 Market Forecast by Therapies (2023-2033)
- 15.5.3 Richter's Syndrome - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Richter's Syndrome - Market Size
    - 15.6.1.1 Market Size (2017-2022)
    - 15.6.1.2 Market Forecast (2023-2033)
  - 15.6.2 Richter's Syndrome - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2017-2022)
    - 15.6.2.2 Market Forecast by Therapies (2023-2033)
  - 15.6.3 Richter's Syndrome - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Richter's Syndrome - Market Size
    - 15.7.1.1 Market Size (2017-2022)
    - 15.7.1.2 Market Forecast (2023-2033)
  - 15.7.2 Richter's Syndrome - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2017-2022)
    - 15.7.2.2 Market Forecast by Therapies (2023-2033)
  - 15.7.3 Richter's Syndrome - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Richter's Syndrome - Market Size
    - 15.8.1.1 Market Size (2017-2022)
    - 15.8.1.2 Market Forecast (2023-2033)
  - 15.8.2 Richter's Syndrome - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2017-2022)
    - 15.8.2.2 Market Forecast by Therapies (2023-2033)
  - 15.8.3 Richter's Syndrome - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Richter's Syndrome - Market Size
    - 15.9.1.1 Market Size (2017-2022)
    - 15.9.1.2 Market Forecast (2023-2033)
  - 15.9.2 Richter's Syndrome - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2017-2022)
    - 15.9.2.2 Market Forecast by Therapies (2023-2033)
  - 15.9.3 Richter's Syndrome - Access and Reimbursement Overview

## **16 RICHTER'S SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 RICHTER'S SYNDROME MARKET - SWOT ANALYSIS**

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

## **18 RICHTER'S SYNDROME MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Richter's Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033

Product link: <https://marketpublishers.com/r/RF33B0307620EN.html>

Price: US\$ 5,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RF33B0307620EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

